Brinker Capital Investments’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-84,693
Closed -$798K 1909
2024
Q4
$798K Sell
84,693
-7,955
-9% -$82.7K 0.01% 1159
2024
Q3
$989K Sell
92,648
-54,140
-37% -$590K 0.01% 1039
2024
Q2
$1.46M Sell
146,788
-5,399
-4% -$55.4K 0.02% 798
2024
Q1
$1.79M Buy
152,187
+12,559
+9% +$161K 0.02% 709
2023
Q4
$1.96M Sell
139,628
-14,731
-10% -$167K 0.02% 643
2023
Q3
$1.88M Sell
154,359
-5,157
-3% -$66.5K 0.02% 642
2023
Q2
$2M Sell
159,516
-5,476
-3% -$65K 0.02% 651
2023
Q1
$1.83M Buy
164,992
+652
+0.4% +$8.04K 0.02% 633
2022
Q4
$2.01M Buy
164,340
+39,293
+31% +$442K 0.04% 483
2022
Q3
$1.3M Buy
125,047
+19,860
+19% +$221K 0.03% 601
2022
Q2
$1.13M Buy
105,187
+3,703
+4% +$30.5K 0.02% 690
2022
Q1
$961K Sell
101,484
-35,339
-26% -$331K 0.01% 808
2021
Q4
$1.58M Buy
136,823
+38,095
+39% +$425K 0.02% 659
2021
Q3
$952K Hold
98,728
0.02% 792
2021
Q2
$952K Buy
98,728
+21,865
+28% +$213K 0.01% 846
2021
Q1
$759K Buy
+76,863
New +$1.19M 0.01% 781

Other funds holding FOLD

Brinker Capital Investments's FOLD Position: Q1 2025 in Review

Brinker Capital Investments sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 84,693 shares — an estimated $798K sold.

Brinker Capital Investments first reported a position in FOLD in Q1 2021 and held it in 16 quarters. The position peaked at $2.01M in Q4 2022. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.

  • Brinker Capital Investments reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Brinker Capital Investments sold 84,693 Amicus Therapeutics shares in Q1 2025, an estimated $798K.
  • Brinker Capital Investments first reported a position in Amicus Therapeutics in Q1 2021 and held it in 16 quarters.
  • Brinker Capital Investments's Amicus Therapeutics position peaked at $2.01M in Q4 2022.
  • 286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.

Based on Brinker Capital Investments's 13F filing for Q1 2025, filed 1 Aug 2025.